Look back at pharma news to Aug 25
By Barbara Obstoj-Cardwell. Editor
Among the political news to emerge last week, two members of the US House of Representatives initiated an investigation of skyrocketing price hikes for multiple sclerosis drugs. On the corporate front, Adamas Pharmaceuticals gained US approval of a new Parkinson’s disease drug, ADS-5102, positive new trial data on Johnson & Johnson’s cancer drug Darzalex, Ironwood Pharmaceuticals receiving a Food and Drug Administration nod for its gout drug Duzallo, and European and US regulatory filing acceptances for Vertex Pharmaceutical’s cystic fibrosis combination drug tezacaftor/ivacaftor.
Multiple sclerosis probe on costs
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze